Authored by Carter Hensley, CPC (AAPC), One O Seven RCM.
Ideal For: Patients with: Leaky Gut Syndrome, IBS, IBD (Crohns, Ulcerative Colitis), acid reflux, stomach ulcers, or general digestive inflammation
Potential Benefits & Side Effects Observations from preclinical and early research literature
From the bulletin: Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization
When Progress Stalls If the documented protocol is running and observed changes flatten, the research-troubleshooting ladder is to check variables in order before touching the dose: Verify reconstitution
ran early-phase ulcerative colitis trials (PL 14736 designation)